Literature DB >> 7199483

Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride.

P G Crosignani, C Ferrari, A Liuzzi, R Benco, A Mattei, P Rampini, D Dellabonzana, C Scarduelli, B Spelta.   

Abstract

One hundred ninety-one hyperprolactinemic patients (78 women and 13 men; 54 with pituitary macroadenoma, 53 with microadenoma, and 84 with idiopathic disease) were treated for 2 to 48 months with one or two of the following prolactin (PRL)-lowering drugs: bromocriptine, metergoline, and lisuride. All of the three drugs used were highly effective in lowering PRL levels and restoring gonadal function both in females and in males in the majority of patients with either idiopathic or tumorous disease. In poorly responsive patients, increasing the drug doses resulted in further PRL lowering for all the three drugs. Mild side effects were frequently encountered with initiation of drug treatment but spontaneously subsided in most cases; severe side effects, necessitating stopping of the treatment, occurred in only 12 instances, but changing of the drug allowed PRL-lowering treatment to be continued in 11 of them.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199483     DOI: 10.1016/s0015-0282(16)45978-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  6 in total

Review 1.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.

Authors:  S Cannavò; L Curtò; S Squadrito; B Almoto; A Vieni; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

Review 3.  A practical guide to the diagnosis and management of amenorrhoea.

Authors:  P G Crosignani; W Vegetti
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  Dopaminergic resistance in a case of invasive macroprolactinoma.

Authors:  D Schwarzstein; A García-Patterson; G Giménez; J Calaf; M Puig-Domingo; A Caixàs; X Matías-Guiu; S M Webb
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

Review 5.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.

Authors:  C Jaspers; G Benker; D Reinwein
Journal:  Clin Investig       Date:  1994-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.